Table 3.
Disease-free survival event | EC-wP (n = 261) | EP-wP (n = 260) |
---|---|---|
No. (%) | No. (%) | |
Local and regional recurrence | 10 (3.8) | 7 (2.7) |
Distant metastasis | 34 (13.0) | 23 (8.8) |
Contralateral breast tumor | 5 (1.9) | 4 (1.5) |
Second primary malignancy | 3 (1.1) | 4 (1.5) |
Death | 1 (0.4) | 1 (0.4) |
Total | 53 (20.2) | 39 (14.9) |
EC-wP = epirubicin/cyclophosphamide followed by weekly paclitaxel; EP-wP = epirubicin/paclitaxel followed by weekly paclitaxel.